Metformin ameliorates the severity of experimental Alport syndrome
Abstract Metformin is widely used for the treatment of type 2 diabetes, and increasing numbers of studies have shown that metformin also ameliorates tumor progression, inflammatory disease, and fibrosis. However, the ability of metformin to improve non-diabetic glomerular disease and chronic kidney...
Guardado en:
Autores principales: | Kohei Omachi, Shota Kaseda, Tsubasa Yokota, Misato Kamura, Keisuke Teramoto, Jun Kuwazuru, Haruka Kojima, Hirofumi Nohara, Kosuke Koyama, Sumio Ohtsuki, Shogo Misumi, Toru Takeo, Naomi Nakagata, Jian-Dong Li, Tsuyoshi Shuto, Mary Ann Suico, Jeffrey H. Miner, Hirofumi Kai |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d6c03b25c7634eeda9e0874c08df981e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5
por: Tomohiko Yamamura, et al.
Publicado: (2020) -
Glomerular endothelial cell heterogeneity in Alport syndrome
por: Hasmik Soloyan, et al.
Publicado: (2020) -
Síndrome hemofagocítico en un trasplantado renal con síndrome de Alport
por: Vega,Jorge, et al.
Publicado: (2013) -
Repercusiones oculares del Síndrome de Alport: A propósito de dos casos
por: Jones,Alex, et al.
Publicado: (2019) -
Single, Double and Triple Blockade of RAAS in Alport Syndrome: Different Tools to Freeze the Evolution of the Disease
por: Antonio Mastrangelo, et al.
Publicado: (2021)